(AOF) – Ose Immunotherapeutics announces the entry into force of the global license to develop an innovative monoclonal antibody in the treatment of chronic inflammation. The biotech announces the end of the waiting period provided for by the Hart-Scott-Rodino Antitrust Improvements Act relating to the worldwide license granted to AbbVie for the development of OSE-230, a monoclonal antibody at the preclinical stage, in the resolution chronic and severe inflammation.
Under the partnership agreement announced on February 28, 2024, Ose Immunotherapeutics has granted an exclusive global license to AbbVie to develop OSE-230, a monoclonal antibody designed for the resolution of chronic inflammation.
Under the terms of the agreement, Ose will now receive the anticipated upfront payment of $48 million and may receive up to an additional $665 million in development, regulatory and commercialization milestone payments and potential tiered royalties on sales. global net of OSE-230.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.